Literature DB >> 11185526

Increased activity and intranuclear expression of phospholipase D2 in human renal cancer.

Y Zhao1, H Ehara, Y Akao, M Shamoto, Y Nakagawa, Y Banno, T Deguchi, N Ohishi, K Yagi, Y Nozawa.   

Abstract

We examined the PLD activities of human renal cancers and found that the PLD2 activity was greatly elevated in almost all cases examined as compared with the adjacent normal region. Western blot analysis showed the increased levels of PLD2 protein, but the PLD1 was not discernible. The oleate-dependent PU) activity was very low but appeared to increase in most cases. Interestingly, the immunohistochemical observations indicated the high expression of PLD2 in the nuclei of clear carcinoma cells. This is the first demonstration which suggests the possible involvement of PLD2 in tumorigenesis of renal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11185526     DOI: 10.1006/bbrc.2000.3719

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  56 in total

1.  Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6.

Authors:  Lizhong Xu; Paul Frankel; Desmond Jackson; Thuy Rotunda; Rita L Boshans; Crislyn D'Souza-Schorey; David A Foster
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

2.  Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.

Authors:  Robert R Lavieri; Sarah A Scott; Paige E Selvy; Kwangho Kim; Satyawan Jadhav; Ryan D Morrison; J Scott Daniels; H Alex Brown; Craig W Lindsley
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

3.  The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion.

Authors:  Ramya Ganesan; Elizabeth Mallets; Julian Gomez-Cambronero
Journal:  Mol Oncol       Date:  2015-12-19       Impact factor: 6.603

4.  A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation.

Authors:  Karen M Henkels; Hong-Juan Peng; Kathleen Frondorf; Julian Gomez-Cambronero
Journal:  Mol Cell Biol       Date:  2010-02-22       Impact factor: 4.272

Review 5.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.

Authors:  David A Foster
Journal:  Biochim Biophys Acta       Date:  2009-03-02

Review 6.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 7.  Phospholipase D/phosphatidic acid signal transduction: role and physiological significance in lung.

Authors:  Rhett Cummings; Narasimham Parinandi; Lixin Wang; Peter Usatyuk; Viswanathan Natarajan
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

8.  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.

Authors:  Robert Lavieri; Sarah A Scott; Jana A Lewis; Paige E Selvy; Michelle D Armstrong; H Alex Brown; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2009-03-06       Impact factor: 2.823

Review 9.  Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.

Authors:  Wenjuan Su; Qin Chen; Michael A Frohman
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

10.  The expression and cellular localization of phospholipase D isozymes in the developing mouse testis.

Authors:  Seungjoon Kim; Heechul Kim; Yongduk Lee; Jin Won Hyun; Young Ho Lee; Min Kyoung Shin; Do Sik Min; Taekyun Shin
Journal:  J Vet Sci       Date:  2007-09       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.